Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04083144
Other study ID # 051/2017
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 22, 2019
Est. completion date December 30, 2022

Study information

Verified date April 2023
Source Centre for Addiction and Mental Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of deep repetitive transcranial magnetic stimulation (rTMS) using the insula H-coil on smoking outcomes in smokers receiving varenicline. It is hypothesized that active deep rTMS will improve abstinence rates, attenuate craving and reduce cigarette consumption and dependence severity.


Description:

This study will be a randomized, double-blind, sham-controlled clinical trial. Nicotine dependent participants will be recruited and randomized tor receive either active or sham rTMS intervention for 4 weeks (5 sessions/week). All participants will receive an open-label treatment of varenicline for 12 weeks and weekly counselling sessions. The aims of the study are: 1. To examine the efficacy of bilateral deep rTMS to the insula on point prevalence smoking abstinence in smokers receiving varenicline treatment. 2. To examine the efficacy of bilateral deep rTMS to the insula on other smoking outcomes such as craving, cigarette smoking and dependence severity. 3. To examine the effect of bilateral deep rTMS to the insula on abstinence at the end of rTMS treatment and at 6-month follow up. Abstinence will be measured by point prevalence at week 4 and 12 and prolonged continuous abstinence at week 26. This will be confirmed using plasma cotinine levels. All other measures will be done using various questionnaires such as Fagerstrom Test of Nicotine Dependence (FTND), Timeline Follow-Back (TLFB), Minnesota Nicotine Withdrawal Scale (MNWS), and Tiffany Questionnaire of Smoking Urges (T-QSU).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 30, 2022
Est. primary completion date September 13, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18-65; - Nicotine dependent as assessed by Diagnostic and Statistical Manual of Mental Disorders (DSM-V); - Reported daily cigarette consumption = 10 and expired carbon monoxide (CO) measurement of = 10 ppm; - Fagerstrom Test of Nicotine Dependence (FTND) = 4; - Reported motivation to quit within 30 days as assessed using the Contemplation Ladder score of = 7. Exclusion Criteria: - Reported smoking abstinence in the 3 months preceding screening visit; - Current use of other smoking cessation aids; - Allergy and/or contraindication to varenicline or rTMS; - Pregnancy, trying to become pregnant or breastfeeding; - Current or recent history of cardiovascular or cerebrovascular disease and/or current hypertension; - Current or historical evidence of suicidal behavior; - Serious current or personal history of medical condition/disease (neurological disorders, brain lesions, multiple sclerosis, head trauma, loss of consciousness, hearing loss, etc.); - Current, personal history or family history of seizures; - Cognitive impairment as defined as a Mini Mental State Examination (MMSE) score <24; - Concomitant use of medication that lowers seizure threshold

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Deep Repetitive Transcranial Magnetic Stimulation (Active)
Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
Deep Repetitive Transcranial Magnetic Stimulation (Sham)
Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
Drug:
Varenicline
12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).

Locations

Country Name City State
Canada Centre for Addiction and Mental Health Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
Centre for Addiction and Mental Health Brainsway, Pfizer

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Point prevalence abstinence at the end of 12 weeks Measured by self-report of smoking abstinence in the past 7 days and confirmed using plasma cotinine measurement. 12 weeks
Secondary Fagerstrom Test For Nicotine Dependence (FTND) score This will be used to assess physical dependence severity in participants. It is a 6 item scale and total scores can range from 0-10. A higher score indicates more severe nicotine dependence. 26 weeks
Secondary Expired CO Measurements This will be used as a biological confirmation of recent smoking. 26 weeks
Secondary Cigarettes per day (TLFB) Self-reported measure of cigarette consumption. 26 weeks
Secondary Minnesota Nicotine Withdrawal Scale (MNWS) score This will be used to assess withdrawal symptoms. It is an 8 item scale and total scores range from 0 to 24. A higher score indicates more severe nicotine withdrawal. 26 weeks
Secondary Tiffany Questionnaire for Smoking Urges (T-QSU) score This will be used to assess symptoms of craving/urges for tobacco. It is a 32 item scale and total scores range from 0 to 224. A higher score indicates more severe smoking craving/urges. 26 weeks
Secondary Point prevalence abstinence at the end of 4 weeks Measured by self-report of smoking abstinence in the past 7 days and confirmed using plasma cotinine measurement. 4 weeks
Secondary Prolonged abstinence from end of treatment (Week 12) to end of follow up (Week 26) Measured by self-report of smoking abstinence since the last visit and confirmed using plasma cotinine measurement. 26 weeks
Secondary Prolonged abstinence with 2-week grace period at end of follow up (Week 26) Measured by self-report of smoking abstinence since the last visit and confirmed using plasma cotinine measurement. 26 weeks
Secondary Continuous abstinence at 6 months Measured by self-report of smoking abstinence since the last visit and confirmed using plasma cotinine measurement. 26 weeks
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Not yet recruiting NCT06307496 - VIDeOS for Smoking Cessation N/A
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A